- Published on
KembaraXtra-Medicine- Acute Coronary Syndrome
Acute coronary syndrome (ACS) refers to a spectrum of life-threatening clinical conditions caused by a sudden reduction in blood flow to the myocardium. It most commonly results from rupture or erosion of a vulnerable atherosclerotic plaque in a coronary artery, followed by platelet activation and thrombus formation. ACS carries high morbidity and mortality, often requiring immediate diagnosis and intervention. Modern management relies on standardized, protocol-driven medical and interventional strategies aimed at rapid restoration of coronary blood flow and prevention of recurrent ischemic events.
ACS encompasses three related clinical entities: ST-elevation myocardial infarction (STEMI), non–ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). STEMI represents the most severe form and is characterized by ST-segment elevation on electrocardiography (ECG) in the appropriate clinical setting, typically reflecting complete coronary artery occlusion. NSTEMI and UA fall under the category of non–ST-elevation ACS (NSTE-ACS) and are distinguished by the absence of ST-segment elevation; NSTEMI is defined by elevated cardiac biomarkers, whereas UA lacks biomarker elevation. With the advent of high-sensitivity troponin assays, most patients previously diagnosed with UA are now reclassified as NSTEMI, reinforcing the concept that ACS exists along a continuous spectrum of ischemic injury.
In the United States, cardiovascular disease remains the leading cause of death, accounting for approximately 640,000 deaths annually. Each year, an estimated 600,000 new myocardial infarctions and 200,000 recurrent events occur. Approximately 70% of myocardial infarctions are NSTEMI. Although STEMI has higher short-term mortality, patients with NSTE-ACS tend to have worse long-term outcomes because they are generally older and have a higher burden of comorbidities such as diabetes, hypertension, and prior coronary artery disease. The median age at presentation is about 68 years, and men are affected more frequently than women, though cardiovascular disease remains the leading cause of death among women.
Major risk factors for ACS mirror those for atherosclerotic coronary artery disease and include hypertension, diabetes mellitus, dyslipidemia, tobacco use, obesity, and a family history of premature coronary disease. Female-specific risk factors, such as pregnancy-related disorders and early menopause, also contribute. These factors promote endothelial dysfunction, plaque formation, and progression to plaque instability and rupture.
Clinically, ACS most often presents with chest discomfort described as pressure or heaviness, typically substernal, and often radiating to the neck, jaw, shoulders, or back. Symptoms may be accompanied by diaphoresis, dyspnea, nausea, or fatigue. Certain populations—including women, elderly patients, individuals with diabetes, and postoperative patients—frequently present atypically, sometimes without chest pain. Unstable angina may manifest as rest angina, new-onset severe angina, or previously stable angina that has become more frequent, prolonged, or severe. Physical examination findings alone are insufficient for diagnosis but are important for assessing hemodynamic stability and identifying complications such as heart failure or cardiogenic shock.
The pathophysiologic hallmark of ACS is rupture of a vulnerable atherosclerotic plaque with a thin fibrous cap and lipid-rich core. Plaque rupture triggers platelet aggregation and thrombus formation, leading to partial or complete coronary artery occlusion. STEMI typically results from complete occlusion, whereas NSTEMI usually reflects subtotal obstruction or transient occlusion. Interestingly, angiographic studies show that many culprit lesions were only moderately stenotic prior to rupture.
Diagnosis of ACS relies on a combination of clinical assessment, ECG findings, and cardiac biomarkers. A 12-lead ECG should be obtained promptly in all patients with suspected ACS, as it guides immediate management. Cardiac troponin is the gold-standard biomarker for myocardial injury, and serial measurements help distinguish acute infarction from other causes of myocardial damage. High-sensitivity troponin assays allow earlier diagnosis or exclusion of myocardial infarction, often within a few hours of presentation. Additional testing, such as chest radiography, echocardiography, or coronary CT angiography, may aid in diagnosis or exclude alternative causes of chest pain.
Risk stratification is a key component of ACS management. Clinical risk scores such as TIMI, GRACE, and HEART integrate patient characteristics, ECG changes, biomarker levels, and clinical presentation to estimate short- and intermediate-term risk. These tools help guide decisions regarding invasive versus conservative strategies and the urgency of coronary angiography.
Treatment of ACS focuses on relieving ischemia, preventing thrombus propagation, and reducing future cardiovascular risk. STEMI is a true medical emergency and requires immediate reperfusion therapy. Primary percutaneous coronary intervention (PCI) is preferred and should be performed within 90 minutes of first medical contact when available. If timely PCI is not possible, fibrinolytic therapy should be administered within 12 hours of symptom onset in eligible patients, followed by transfer to a PCI-capable center. In NSTE-ACS, management is guided by risk stratification, with high-risk patients benefiting from an early invasive strategy and lower-risk patients managed initially with intensive medical therapy.
Medical management includes dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, anticoagulation, beta-blockers, nitrates, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers when indicated. Oxygen is reserved for patients with hypoxemia, and morphine may be used cautiously for refractory pain. Long-term therapy after ACS emphasizes secondary prevention through aggressive risk-factor modification, adherence to guideline-directed medical therapy, and participation in cardiac rehabilitation programs.
All patients with ACS should be managed in close collaboration with cardiology specialists, and selected patients may require referral for coronary artery bypass grafting. Early recognition, rapid risk stratification, and timely reperfusion remain the cornerstones of improving survival and long-term outcomes in acute coronary syndrome.
Acute coronary syndrome (ACS) refers to a spectrum of life-threatening clinical conditions caused by a sudden reduction in blood flow to the myocardium. It most commonly results from rupture or erosion of a vulnerable atherosclerotic plaque in a coronary artery, followed by platelet activation and thrombus formation. ACS carries high morbidity and mortality, often requiring immediate diagnosis and intervention. Modern management relies on standardized, protocol-driven medical and interventional strategies aimed at rapid restoration of coronary blood flow and prevention of recurrent ischemic events.
ACS encompasses three related clinical entities: ST-elevation myocardial infarction (STEMI), non–ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). STEMI represents the most severe form and is characterized by ST-segment elevation on electrocardiography (ECG) in the appropriate clinical setting, typically reflecting complete coronary artery occlusion. NSTEMI and UA fall under the category of non–ST-elevation ACS (NSTE-ACS) and are distinguished by the absence of ST-segment elevation; NSTEMI is defined by elevated cardiac biomarkers, whereas UA lacks biomarker elevation. With the advent of high-sensitivity troponin assays, most patients previously diagnosed with UA are now reclassified as NSTEMI, reinforcing the concept that ACS exists along a continuous spectrum of ischemic injury.
In the United States, cardiovascular disease remains the leading cause of death, accounting for approximately 640,000 deaths annually. Each year, an estimated 600,000 new myocardial infarctions and 200,000 recurrent events occur. Approximately 70% of myocardial infarctions are NSTEMI. Although STEMI has higher short-term mortality, patients with NSTE-ACS tend to have worse long-term outcomes because they are generally older and have a higher burden of comorbidities such as diabetes, hypertension, and prior coronary artery disease. The median age at presentation is about 68 years, and men are affected more frequently than women, though cardiovascular disease remains the leading cause of death among women.
Major risk factors for ACS mirror those for atherosclerotic coronary artery disease and include hypertension, diabetes mellitus, dyslipidemia, tobacco use, obesity, and a family history of premature coronary disease. Female-specific risk factors, such as pregnancy-related disorders and early menopause, also contribute. These factors promote endothelial dysfunction, plaque formation, and progression to plaque instability and rupture.
Clinically, ACS most often presents with chest discomfort described as pressure or heaviness, typically substernal, and often radiating to the neck, jaw, shoulders, or back. Symptoms may be accompanied by diaphoresis, dyspnea, nausea, or fatigue. Certain populations—including women, elderly patients, individuals with diabetes, and postoperative patients—frequently present atypically, sometimes without chest pain. Unstable angina may manifest as rest angina, new-onset severe angina, or previously stable angina that has become more frequent, prolonged, or severe. Physical examination findings alone are insufficient for diagnosis but are important for assessing hemodynamic stability and identifying complications such as heart failure or cardiogenic shock.
The pathophysiologic hallmark of ACS is rupture of a vulnerable atherosclerotic plaque with a thin fibrous cap and lipid-rich core. Plaque rupture triggers platelet aggregation and thrombus formation, leading to partial or complete coronary artery occlusion. STEMI typically results from complete occlusion, whereas NSTEMI usually reflects subtotal obstruction or transient occlusion. Interestingly, angiographic studies show that many culprit lesions were only moderately stenotic prior to rupture.
Diagnosis of ACS relies on a combination of clinical assessment, ECG findings, and cardiac biomarkers. A 12-lead ECG should be obtained promptly in all patients with suspected ACS, as it guides immediate management. Cardiac troponin is the gold-standard biomarker for myocardial injury, and serial measurements help distinguish acute infarction from other causes of myocardial damage. High-sensitivity troponin assays allow earlier diagnosis or exclusion of myocardial infarction, often within a few hours of presentation. Additional testing, such as chest radiography, echocardiography, or coronary CT angiography, may aid in diagnosis or exclude alternative causes of chest pain.
Risk stratification is a key component of ACS management. Clinical risk scores such as TIMI, GRACE, and HEART integrate patient characteristics, ECG changes, biomarker levels, and clinical presentation to estimate short- and intermediate-term risk. These tools help guide decisions regarding invasive versus conservative strategies and the urgency of coronary angiography.
Treatment of ACS focuses on relieving ischemia, preventing thrombus propagation, and reducing future cardiovascular risk. STEMI is a true medical emergency and requires immediate reperfusion therapy. Primary percutaneous coronary intervention (PCI) is preferred and should be performed within 90 minutes of first medical contact when available. If timely PCI is not possible, fibrinolytic therapy should be administered within 12 hours of symptom onset in eligible patients, followed by transfer to a PCI-capable center. In NSTE-ACS, management is guided by risk stratification, with high-risk patients benefiting from an early invasive strategy and lower-risk patients managed initially with intensive medical therapy.
Medical management includes dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, anticoagulation, beta-blockers, nitrates, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers when indicated. Oxygen is reserved for patients with hypoxemia, and morphine may be used cautiously for refractory pain. Long-term therapy after ACS emphasizes secondary prevention through aggressive risk-factor modification, adherence to guideline-directed medical therapy, and participation in cardiac rehabilitation programs.
All patients with ACS should be managed in close collaboration with cardiology specialists, and selected patients may require referral for coronary artery bypass grafting. Early recognition, rapid risk stratification, and timely reperfusion remain the cornerstones of improving survival and long-term outcomes in acute coronary syndrome.
0 Comments
